Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.15 is 149% below its 2-year average of -0.06, around the middle of its 2-year range (-0.48–0.17).
As of the fiscal period ended Tuesday, March 31, 2026. 23.95% above its 12-month average of -0.19.
Reported quarterly debt to equity ratio; no daily interpolation. Q3 FY2025 (2026-03-31): -0.15.
DEBT TO EQUITY RATIO
-0.15
DEBT TO EQUITY RATIO AVG TTM
-0.19
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+23.95%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 586 covered companies
CURRENT VS SECTOR MEDIAN
-213.64%
vs the sector median at left
Lunai Bioworks Inc.
Market Cap
$5.21M
Debt to Equity Ratio
-0.15
TTM Avg
-0.19
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.23M
Debt to Equity Ratio
4.80
TTM Avg
6.38
3Y Avg
6.38
5Y Avg
6.38
Market Cap
$5.26M
Debt to Equity Ratio
0.33
TTM Avg
0.21
3Y Avg
0.27
5Y Avg
0.18
Market Cap
$5.32M
Debt to Equity Ratio
0.36
TTM Avg
0.26
3Y Avg
0.18
5Y Avg
0.25
Market Cap
$5.29M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.03
Market Cap
$5.28M
Debt to Equity Ratio
1.57
TTM Avg
0.64
3Y Avg
1.33
5Y Avg
1.33
Market Cap
$5.57M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lunai Bioworks Inc. (LNAI) | $5.21M | -0.15 | -0.19 | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.23M | 4.80 | 6.38 | 6.38 | 6.38 |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.26M | 0.33 | 0.21 | 0.27 | 0.18 |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | 0.36 | 0.26 | 0.18 | 0.25 |
| CalciMedica, Inc. (CALC)vs › | $4.95M | 0.00 | 0.00 | 0.00 | 0.92 |
| Imunon, Inc. (IMNN)vs › | $5.08M | 1.87 | 0.21 | 0.18 | 0.20 |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | 0.00 | 0.00 | 0.00 | 0.03 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.28M | 1.57 | 0.64 | 1.33 | 1.33 |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.57M | 0.00 | 0.00 | 0.00 | 0.00 |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.74M | 0.02 | 0.03 | 0.03 | 0.03 |
Debt/Equity
-0.15
Current Ratio
0.19
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-03-31 | -0.15 |
| 2025-12-31 | -0.22 |
| 2025-09-30 | -0.21 |
| 2025-06-30 | -0.48 |
| 2025-03-31 | 0.08 |
| 2024-12-31 | 0.08 |
| 2024-09-30 | 0.04 |
| 2024-06-30 | 0.03 |
| 2024-03-31 | 0.06 |
| 2023-12-31 | 0.17 |
